Comment on: Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials
British Journal of Surgery · 2024
DOI: 10.1093/bjs/znae085 ↗Kurz gefasst
Kommentar in der Zeitschrift British Journal of Surgery, 2024. Verfasst von Patrick W Underwood und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenocarcinoma. Die Arbeit nennt 1 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
ORCID-Profile: Patrick W Underwood
Zitieren
APA
Underwood, P. W., & Cloyd, J. M. (2024). Comment on: Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials. British Journal of Surgery. https://doi.org/10.1093/bjs/znae085
Vancouver
Underwood PW, Cloyd JM. Comment on: Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials. British Journal of Surgery. 2024. doi:10.1093/bjs/znae085
BibTeX
@article{Underwood2024,
author = {Underwood, Patrick W and Cloyd, Jordan M},
title = {Comment on: Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials},
journal = {British Journal of Surgery},
year = {2024},
doi = {10.1093/bjs/znae085}
}
EUVIMED